Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05329103 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by Peel Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 7
- Study locations
NCT05329103: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Peel Therapeutics.
NCT05329103 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Peel Therapeutics. The registered enrollment target is 65 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (66% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05329103, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Peel Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.
Primary Outcome
Frequency, severity, and relatedness of dose limiting toxicities
Conditions Studied
Interventions
- DRUG PEEL-224
- DRUG FOLF+B
Study Locations (7)
Arizona
- HonorHealth Research Institiute - Scottsdale
California
- Stanford Cancer Center - Palo Alto
North Carolina
- Carolina BioOncology Institute - Huntersville
Pennsylvania
- Abramson Cancer Center at Pennsylvania Hospital - Philadelphia
Texas
- Mary Crowley Cancer Research - Dallas
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2022-07-11 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What NCT05329103 shows while recruiting
NCT05329103 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which PEEL-224 is the first listed.
NCT05329103 lists 7 locations in 7 states (Arizona, California, North Carolina).
Frequently Asked Questions
What is clinical trial NCT05329103 about?
NCT05329103 is a clinical study titled "A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors". This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.
What is the current status of trial NCT05329103?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2022-07-11. Estimated completion is 2026-03.
What conditions does trial NCT05329103 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT05329103?
The interventions under investigation include: PEEL-224 (DRUG), FOLF+B (DRUG).
Who is sponsoring clinical trial NCT05329103?
This trial is sponsored by Peel Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05329103 being conducted?
This trial has 7 study locations across Arizona, California, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05329103's enrollment target sits among peer trials
65 150th of 189 higher than 39 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI